<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39415027</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Immunomodulatory effect of IFN-γ licensed adipose-mesenchymal stromal cells in an in vitro model of inflammation generated by SARS-CoV-2 antigens.</ArticleTitle><Pagination><StartPage>24235</StartPage><MedlinePgn>24235</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24235</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-75776-5</ELocationID><Abstract><AbstractText>In recent years, clinical studies have shown positive results of the application of Mesenchymal Stromal Cells (MSCs) in severe cases of COVID-19. However, the mechanisms of immunomodulation of IFN-γ licensed MSCs in SARS-CoV-2 infection are only partially understood. In this study, we first tested the effect of IFN-γ licensing in the MSC immunomodulatory profile. Then, we established an in vitro model of inflammation by exposing Calu-3 lung cells to SARS-CoV-2 nucleocapsid and spike (NS) antigens, and determined the toxicity of SARS-CoV-2 NS antigen and/or IFN-γ stimulation to Calu-3. The conditioned medium (iCM) generated by Calu-3 cells exposed to IFN-γ and SARS-CoV-2 NS antigens was used to stimulate T-cells, which were then co-cultured with IFN-γ-licensed MSCs. The exposure to IFN-γ and SARS-CoV-2 NS antigens compromised the viability of Calu-3 cells and induced the expression of the inflammatory mediators ICAM-1, CXCL-10, and IFN-β by these cells. Importantly, despite initially stimulating T-cell activation, IFN-γ-licensed MSCs dramatically reduced IL-6 and IL-10 levels secreted by T-cells exposed to NS antigens and iCM. Moreover, IFN-γ-licensed MSCs were able to significantly inhibit T-cell apoptosis induced by SARS-CoV-2 NS antigens. Taken together, our data show that, in addition to reducing the level of critical cytokines in COVID-19, IFN-γ-licensed MSCs protect T-cells from SARS-CoV-2 antigen-induced apoptosis. Such observations suggest that MSCs may contribute to COVID-19 management by preventing the lymphopenia and immunodeficiency observed in critical cases of the disease.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bispo</LastName><ForeName>Elizabete Cristina Iseke</ForeName><Initials>ECI</Initials><AffiliationInfo><Affiliation>Laboratory of Hematology and Stem Cells (LHCT), Faculty of Health Sciences, University of Brasília, Brasília, 70910-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Argañaraz</LastName><ForeName>Enrique Roberto</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular NeuroVirology, Faculty of Health Sciences, University of Brasília, Brasília, 70910-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neves</LastName><ForeName>Franscisco de Assis Rocha</ForeName><Initials>FAR</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Pharmacology, Faculty of Health Sciences, University of Brasília, Brasília, 70910-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Carvalho</LastName><ForeName>Juliana Lott</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Interdisciplinary Laboratory of Bioscience, Faculty of Medicine, University of Brasília, Brasília, 70910-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saldanha-Araujo</LastName><ForeName>Felipe</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratory of Hematology and Stem Cells (LHCT), Faculty of Health Sciences, University of Brasília, Brasília, 70910-900, Brazil. felipearaujo@unb.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086462">Coronavirus Nucleocapsid Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="Y">Mesenchymal Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="Y">Interferon-gamma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056747" MajorTopicYN="N">Immunomodulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086462" MajorTopicYN="N">Coronavirus Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IFN-γ</Keyword><Keyword MajorTopicYN="N">Mesenchymal stem cells</Keyword><Keyword MajorTopicYN="N">Nucleocapsid</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Spike</Keyword><Keyword MajorTopicYN="N">T-cells</Keyword></KeywordList><CoiStatement>The authors declare that there are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>23</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39415027</ArticleId><ArticleId IdType="pmc">PMC11484699</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-75776-5</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-75776-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pittenger, M. F. et al. Multilineage potential of adult human mesenchymal stem cells. Science. 284, 143–147 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10102814</ArticleId></ArticleIdList></Reference><Reference><Citation>Covas, D. T. et al. Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146 + perivascular cells and fibroblasts. Exp. Hematol.36, 642–654 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18295964</ArticleId></ArticleIdList></Reference><Reference><Citation>Campagnoli, C. et al. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood. 98, 2396–2402 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11588036</ArticleId></ArticleIdList></Reference><Reference><Citation>in ’t Anker, P. S. et al. Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica. 88, 845–852 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12935972</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagar, R., Walther-Jallow, L., David, A. L., Götherström, C. &amp; Westgren, M. Fetal mesenchymal stromal cells: an opportunity for prenatal Cellular Therapy. Curr. Stem Cell. Rep.4, 61–68 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5866262</ArticleId><ArticleId IdType="pubmed">29600162</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Z. Y. et al. Superior osteogenic capacity for bone tissue engineering of fetal compared with perinatal and adult mesenchymal stem cells. Stem Cells. 27, 126–137 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">18832592</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi, Y. et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat. Rev. Nephrol.14, 493–507 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29895977</ArticleId></ArticleIdList></Reference><Reference><Citation>Margiana, R. et al. Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review. Stem Cell. Res. Ther.13, 366 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9330677</ArticleId><ArticleId IdType="pubmed">35902958</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, T. et al. Challenges and advances in clinical applications of mesenchymal stromal cells. J. Hematol. Oncol.14, 24 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7880217</ArticleId><ArticleId IdType="pubmed">33579329</ArticleId></ArticleIdList></Reference><Reference><Citation>Maccario, R. et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4 + T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 90, 516–525 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15820948</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubtsov, Y. et al. Molecular mechanisms of Immunomodulation properties of mesenchymal stromal cells: a New Insight into the role of ICAM-1. Stem Cells Int. 2017, 6516854 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5518497</ArticleId><ArticleId IdType="pubmed">28761447</ArticleId></ArticleIdList></Reference><Reference><Citation>Saldanha-Araujo, F. et al. Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes. Stem Cell. Res.7, 66–74 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21546330</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Nicola, M. et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 99, 3838–3843 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11986244</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisel, R. et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 103, 4619–4621 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15001472</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, S. H. et al. Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp. Mol. Med.41, 315–324 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2701980</ArticleId><ArticleId IdType="pubmed">19307751</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, H., Lee, R. H., Bazhanov, N., Oh, J. Y. &amp; Prockop, D. J. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages. Blood. 118, 330–338 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3138686</ArticleId><ArticleId IdType="pubmed">21551236</ArticleId></ArticleIdList></Reference><Reference><Citation>Galleu, A. et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci. Transl Med.9, eaam7828 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29141887</ArticleId></ArticleIdList></Reference><Reference><Citation>de Noronha, N. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell. Res. Ther.10, 131 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6498654</ArticleId><ArticleId IdType="pubmed">31046833</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho, A. É. S., Sousa, M. R. R., Alencar-Silva, T., Carvalho, J. L. &amp; Saldanha-Araujo, F. Mesenchymal stem cells immunomodulation: the road to IFN-γ licensing and the path ahead. Cytokine Growth Factor. Rev.47, 32–42 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31129018</ArticleId></ArticleIdList></Reference><Reference><Citation>Serejo, T. R. T. et al. Assessment of the Immunosuppressive Potential of INF-γ Licensed Adipose Mesenchymal Stem Cells, Their Secretome and Extracellular Vesicles. Cells 8, (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6356584</ArticleId><ArticleId IdType="pubmed">30621275</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinnadurai, R. et al. Cryopreserved mesenchymal stromal cells are susceptible to T-Cell mediated apoptosis which is partly rescued by IFNγ Licensing. Stem Cells. 34, 2429–2442 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016228</ArticleId><ArticleId IdType="pubmed">27299362</ArticleId></ArticleIdList></Reference><Reference><Citation>Boberg, E. et al. Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: a phase II study. Stem Cells Transl Med.9, 1190–1202 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7519760</ArticleId><ArticleId IdType="pubmed">32573983</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang, L. et al. Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial. Stem Cell. Res. Ther.13, 180 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9066971</ArticleId><ArticleId IdType="pubmed">35505375</ArticleId></ArticleIdList></Reference><Reference><Citation>Vij, R., Stebbings, K. A., Kim, H., Park, H. &amp; Chang, D. Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I/IIa, open-label, non-randomized pilot trial. Stem Cell. Res. Ther.13, 88 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8896321</ArticleId><ArticleId IdType="pubmed">35241141</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamen, D. L. et al. Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE. Lupus Sci. Med.9, e000704 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9277402</ArticleId><ArticleId IdType="pubmed">35820718</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieujean, S. et al. Mesenchymal stem cell injection in Crohn’s Disease strictures: a phase I-II clinical study. J. Crohns Colitis. 16, 506–510 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34473270</ArticleId></ArticleIdList></Reference><Reference><Citation>Saldanha-Araujo, F., Melgaço Garcez, E., Silva-Carvalho, A. E. &amp; Carvalho, J. L. Mesenchymal stem cells: a New Piece in the puzzle of COVID-19 treatment. Front. Immunol.11, 1563 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7347794</ArticleId><ArticleId IdType="pubmed">32719683</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, M. Y. et al. SARS-CoV-2: structure, Biology, and structure-based therapeutics Development. Front. Cell. Infect. Microbiol.10, 587269 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723891</ArticleId><ArticleId IdType="pubmed">33324574</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong, Y. et al. Nucleocapsid Protein Recruitment to replication-transcription complexes plays a crucial role in Coronaviral Life Cycle. J. Virol.94(4), e01925–19 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6997762</ArticleId><ArticleId IdType="pubmed">31776274</ArticleId></ArticleIdList></Reference><Reference><Citation>Okba, N. M. A. et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific antibody responses in Coronavirus Disease patients. Emerg. Infect. Dis.26, 1478–1488 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323511</ArticleId><ArticleId IdType="pubmed">32267220</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison, A. G., Lin, T. &amp; Wang, P. Mechanisms of SARS-CoV-2 transmission and Pathogenesis. Trends Immunol.41, 1100–1115 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7556779</ArticleId><ArticleId IdType="pubmed">33132005</ArticleId></ArticleIdList></Reference><Reference><Citation>Jocher, G. et al. ADAM10 and ADAM17 promote SARS-CoV-2 cell entry and spike protein-mediated lung cell fusion. EMBO Rep.23, e54305 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9171409</ArticleId><ArticleId IdType="pubmed">35527514</ArticleId></ArticleIdList></Reference><Reference><Citation>Madden, E. A. &amp; Diamond, M. S. Host cell-intrinsic innate immune recognition of SARS-CoV-2. Curr. Opin. Virol.52, 30–38 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8580835</ArticleId><ArticleId IdType="pubmed">34814102</ArticleId></ArticleIdList></Reference><Reference><Citation>Aboudounya, M. M. &amp; Heads, R. J. COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation. Mediators Inflamm. 8874339 (2021). (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811571</ArticleId><ArticleId IdType="pubmed">33505220</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki, R. &amp; Kanneganti, T. D. Innate immunity, cytokine storm, and inflammatory cell death in COVID-19. J. Transl Med.20, 542 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9682745</ArticleId><ArticleId IdType="pubmed">36419185</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, X. COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol.20, 269–270 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7143200</ArticleId><ArticleId IdType="pubmed">32273594</ArticleId></ArticleIdList></Reference><Reference><Citation>Darif, D. et al. The pro-inflammatory cytokines in COVID-19 pathogenesis: what goes wrong? Microb. Pathog. 153, 104799 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7889464</ArticleId><ArticleId IdType="pubmed">33609650</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho, J. L. et al. Production of Human Endothelial Cells Free from Soluble Xenogeneic Antigens for Bioartificial Small Diameter Vascular Graft Endothelization. Biomed Res. Int. 652474 (2015). (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4471259</ArticleId><ArticleId IdType="pubmed">26146626</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva-Carvalho, A. É. et al. GVHD-derived plasma as a priming strategy of mesenchymal stem cells. Stem Cell. Res. Ther.11, 156 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164240</ArticleId><ArticleId IdType="pubmed">32299501</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch, S. et al. Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun. Ageing. 5, 6 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2515281</ArticleId><ArticleId IdType="pubmed">18657274</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak, K. J. &amp; Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25, 402–408 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss, D. J. et al. An International Society for cell and Gene Therapy Mesenchymal Stromal Cells Committee editorial on overcoming limitations in clinical trials of mesenchymal stromal cell therapy for coronavirus disease-19: time for a global registry. Cytotherapy. 24, 1071–1073 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9339970</ArticleId><ArticleId IdType="pubmed">36028438</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers, C. J. et al. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients. J. Transl Med.18, 203 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7232924</ArticleId><ArticleId IdType="pubmed">32423449</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazini, L., Rochette, L., Amine, M. &amp; Malka, G. Regenerative capacity of adipose derived stem cells (ADSCs), comparison with mesenchymal stem cells (MSCs). Int. J. Mol. Sci.20(10), 2523 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6566837</ArticleId><ArticleId IdType="pubmed">31121953</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahani, P. &amp; Datta, I. Mesenchymal stromal cell therapy for coronavirus disease 2019: which? When? And how much? Cytotherapy. 23, 861–873 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084615</ArticleId><ArticleId IdType="pubmed">34053857</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez, J. J., Beaty, D. E., Fruhwirth, L. L., Chaves, L., Riordan, N. H. &amp; A. P. &amp; Dodging COVID-19 infection: low expression and localization of ACE2 and TMPRSS2 in multiple donor-derived lines of human umbilical cord-derived mesenchymal stem cells. J. Transl Med.19, 149 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8045575</ArticleId><ArticleId IdType="pubmed">33853637</ArticleId></ArticleIdList></Reference><Reference><Citation>Generali, M. et al. Heterogeneous expression of ACE2 and TMPRRS2 in mesenchymal stromal cells. J. Cell. Mol. Med.26, 228–234 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8742235</ArticleId><ArticleId IdType="pubmed">34821008</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181, 271–280e8 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustine, J. N. &amp; Jones, D. Immunopathology of Hyperinflammation in COVID-19. Am. J. Pathol.191, 4–17 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484812</ArticleId><ArticleId IdType="pubmed">32919977</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, S. et al. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight5(12), e138070 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7406259</ArticleId><ArticleId IdType="pubmed">32427582</ArticleId></ArticleIdList></Reference><Reference><Citation>Cloer, C. et al. Mesenchymal stromal cell-derived extracellular vesicles reduce lung inflammation and damage in nonclinical acute lung injury: implications for COVID-19. PLoS One. 16, e0259732 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8592477</ArticleId><ArticleId IdType="pubmed">34780505</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, S. et al. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal. Transduct. Target. Ther.5, 235 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7545816</ArticleId><ArticleId IdType="pubmed">33037188</ArticleId></ArticleIdList></Reference><Reference><Citation>Klouda, T. et al. Interferon-alpha or -beta facilitates SARS-CoV-2 pulmonary vascular infection by inducing ACE2. Angiogenesis. 25, 225–240 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8554520</ArticleId><ArticleId IdType="pubmed">34714440</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesmez Can, F., Özkurt, Z., Öztürk, N. &amp; Sezen, S. Effect of IL-6, IL-8/CXCL8, IP-10/CXCL 10 levels on the severity in COVID 19 infection. Int. J. Clin. Pract.75, e14970 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646602</ArticleId><ArticleId IdType="pubmed">34626520</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J. et al. Leptin correlates with monocytes activation and severe condition in COVID-19 patients. J. Leukoc. Biol.110, 9–20 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10016867</ArticleId><ArticleId IdType="pubmed">33404078</ArticleId></ArticleIdList></Reference><Reference><Citation>Spadaro, S. et al. Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patients. Crit. Care. 25, 74 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7894238</ArticleId><ArticleId IdType="pubmed">33608030</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong, M. et al. Elevated expression of serum endothelial cell adhesion molecules in COVID-19 patients. J. Infect. Dis.222, 894–898 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7337874</ArticleId><ArticleId IdType="pubmed">32582936</ArticleId></ArticleIdList></Reference><Reference><Citation>Cibrián, D. &amp; Sánchez-Madrid, F. CD69: from activation marker to metabolic gatekeeper. Eur. J. Immunol.47, 946–953 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6485631</ArticleId><ArticleId IdType="pubmed">28475283</ArticleId></ArticleIdList></Reference><Reference><Citation>Saldanha-Araujo, F. et al. Mesenchymal stem cells promote the sustained expression of CD69 on activated T lymphocytes: roles of canonical and non-canonical NF-κB signalling. J. Cell. Mol. Med.16, 1232–1244 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3823077</ArticleId><ArticleId IdType="pubmed">21777379</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, B. et al. Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent. J. Clin. Invest.117, 3029–3041 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1974869</ArticleId><ArticleId IdType="pubmed">17853940</ArticleId></ArticleIdList></Reference><Reference><Citation>Meckiff, B. J. et al. Imbalance of Regulatory and cytotoxic SARS-CoV-2-Reactive CD4 T cells in COVID-19. Cell. 183, 1340–1353e16 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534589</ArticleId><ArticleId IdType="pubmed">33096020</ArticleId></ArticleIdList></Reference><Reference><Citation>Najar, M. et al. Impact of different mesenchymal stromal cell types on T-cell activation, proliferation and migration. Int. Immunopharmacol.15, 693–702 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23499510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronsteiner, B. et al. Human mesenchymal stem cells from adipose tissue and amnion influence T-cells depending on stimulation method and presence of other immune cells. Stem Cells Dev.20, 2115–2126 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21381973</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva-Carvalho, A. É. et al. Expression of Adhesion molecules, and production of anti-inflammatory factors are differentially modulated by spheroid-cultured mesenchymal stem cells. Int. J. Mol. Sci.23, 14349 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9695986</ArticleId><ArticleId IdType="pubmed">36430835</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian, Y. et al. Unique phenotypes and clonal expansions of human CD4 effector memory T cells re-expressing CD45RA. Nat. Commun.8, 1473 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5684192</ArticleId><ArticleId IdType="pubmed">29133794</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzoni, A. et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J. Clin. Invest.130, 4694–4703 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456250</ArticleId><ArticleId IdType="pubmed">32463803</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudryavtsev, I. V. et al. Heterogenous CD8 + T cell maturation and ‘Polarization’ in Acute and Convalescent COVID-19 patients. Viruses14(9), 1906 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9504186</ArticleId><ArticleId IdType="pubmed">36146713</ArticleId></ArticleIdList></Reference><Reference><Citation>Day, A. J. &amp; Milner, C. M. TSG-6: a multifunctional protein with anti-inflammatory and tissue-protective properties. Matrix Biol.78–79, 60–83 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">29362135</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu, J., Yue, W., Le-Le, Z., Bin, L. &amp; Hu, X. Mesenchymal stem cells inhibit T cell activation by releasing TGF-β1 from TGF-β1/GARP complex. Oncotarget. 8, 99784–99800 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5725131</ArticleId><ArticleId IdType="pubmed">29245940</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehman, J. et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation. 109, 1292–1298 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14993122</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo, H. Y. et al. Fibroblast growth factor 2 decreases bleomycin-induced pulmonary fibrosis and inhibits fibroblast collagen production and myofibroblast differentiation. J. Pathol.246, 54–66 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6175645</ArticleId><ArticleId IdType="pubmed">29873400</ArticleId></ArticleIdList></Reference><Reference><Citation>Karakaş, N. et al. Mesenchymal Stem Cell-Based COVID-19 Therapy: Bioengineering Perspectives. Cells 11, (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8834073</ArticleId><ArticleId IdType="pubmed">35159275</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbari, H. et al. The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Life Sci.258, 118167 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7387997</ArticleId><ArticleId IdType="pubmed">32735885</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, H. et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg. Microbes Infect.9, 1123–1130 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473317</ArticleId><ArticleId IdType="pubmed">32475230</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhar, S. K., Damodar, K. V., Gujar, S., Das, M. &amp; S. &amp; IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression. Heliyon. 7, e06155 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7846230</ArticleId><ArticleId IdType="pubmed">33553782</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam, F. et al. The Association of Cytokines IL-2, IL-6, TNF-α, IFN-γ, and IL-10 with the Disease Severity of COVID-19: a study from Bangladesh. Cureus. 16, e57610 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11069400</ArticleId><ArticleId IdType="pubmed">38707035</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafarzadeh, A., Jafarzadeh, S., Nozari, P., Mokhtari, P. &amp; Nemati, M. Lymphopenia an important immunological abnormality in patients with COVID-19: possible mechanisms. Scand. J. Immunol.93, e12967 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32875598</ArticleId></ArticleIdList></Reference><Reference><Citation>André, S. et al. T cell apoptosis characterizes severe Covid-19 disease. Cell. Death Differ.29, 1486–1499 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8782710</ArticleId><ArticleId IdType="pubmed">35066575</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar, R. &amp; Perlman, S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol.39, 529–539 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7079893</ArticleId><ArticleId IdType="pubmed">28466096</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou, H. et al. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19. Clin. Exp. Immunol.201, 76–84 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267633</ArticleId><ArticleId IdType="pubmed">32365221</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanbari Naeini, L. et al. The Important Role of Interleukin-2 in COVID-19. J Immunol Res 7097329 (2023). (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10465260</ArticleId><ArticleId IdType="pubmed">37649897</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly, E., Won, A., Refaeli, Y. &amp; Van Parijs, L. IL-2 and related cytokines can promote T cell survival by activating AKT. J. Immunol.168, 597–603 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11777951</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>